These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

Aims: Post-infectious gastroparesis (PIGP) is a subgroup of idiopathic gastroparesis. The aim of this study was to identify post-viral gastroparesis and to characterize clinical and ...

It is driven by rising diabetes rates. The global gastroparesis drugs market is set to grow by $1.42b from 2024 to 2028, with ...

Many patients with severe gastroparesis unfortunately do not achieve adequate relief from the previously outlined therapies. In such cases, consideration should be given to implantation of a ...

The symptoms include constant nausea and vomiting. → Common treatment options → Questions to ask your doctor Gastroparesis is said to be caused by damaged nerves of the stomach. Diagnosis includes ...

Report on how AI is redefining market landscape - The global gastroparesis drugs market size is estimated to grow by USD 1.42 ...

“I have a lot of pain in my stomach," she said. "I have a lot of pain in my chest. I feel lots of nausea." Smoot suffers from ...

Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing ...

“The strong response to GIMOTI among healthcare providers and patients underscores its growing value as an innovative ...

Study Finds Ozempic, Wegovy May Increase Gastroparesis, Bowel Obstruction Risks Researchers at the University of British Colombia involved in the JAMA Ozempic and Wegovy study analyzed the ...

Evoke Pharma Inc (NASDAQ:EVOK) shares are trading higher Monday after the company presented GLP-1 data for users with ...

Evoke Pharma Inc. (EVOK) and Eversana Life Science Services, LLC. announced statistically significant comparative data on its study ...